Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Mural Oncology plc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MURA
Nasdaq
2834
www.muraloncology.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Mural Oncology plc
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully
- Feb 11th, 2025 3:55 pm
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
- Jan 9th, 2025 9:00 pm
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec 3rd, 2024 9:15 pm
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
- Nov 24th, 2024 11:10 am
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
- Nov 20th, 2024 9:15 pm
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
- Nov 13th, 2024 12:00 pm
Mural Oncology to Participate in Two Upcoming Investor Conferences
- Nov 11th, 2024 12:00 pm
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Oct 7th, 2024 11:00 am
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
- Sep 26th, 2024 11:00 am
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
- Sep 23rd, 2024 11:00 am
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
- Sep 10th, 2024 11:00 am
Mural Oncology to Present at Two Upcoming Investor Conferences
- Aug 27th, 2024 11:00 am
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
- Aug 13th, 2024 11:15 am
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
- Jul 31st, 2024 11:00 am
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
- Jun 5th, 2024 8:15 pm
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
- May 23rd, 2024 9:00 pm
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
- May 14th, 2024 11:00 am
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apr 24th, 2024 8:00 pm
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
- Apr 9th, 2024 8:00 pm
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
- Mar 26th, 2024 11:00 am
Scroll